Long-term ticagrelor cuts risk of future events after heart attack

16 marzo 2015

Adding the antiplatelet drug ticagrelor to aspirin as long-term therapy after a heart attack significantly reduced the rate of subsequent death from cardiovascular causes, heart attack or stroke, with the benefit appearing to accrue for nearly three years, according to a new study.